The antibiotic trimethoprim targets the bacterial dihydrofolate reductase enzyme and 3 subsequently affects the entire folate network. We present an expanded mathematical model of 4 trimethoprim's action on the Escherichia coli folate network that greatly improves upon Kwon et 5 al. (2008). The improvement upon the Kwon Model lends greater insight into the effects of 6 trimethoprim at higher resolution and accuracy. More importantly, the presented mathematical 7 model enables drug target discovery in a way the earlier model could not. Using the improved 8 mathematical model as a scaffold, we use parameter optimization to search for new drug targets 9 that replicate the effect of trimethoprim. We present the model and model-scaffold strategy as 10 an efficient route for drug target discovery.
We 54 then use the current TM Model as a scaffold for drug target searching by replicating the effects 55 of TM on the E. coli folate network without inhibiting DHFR or FPGS. In doing this we create a 56 Rewired Model that shows a simulated time-course progression similar to the TM Model, but 57 without TM in the simulation. This overall strategy is outlined in Fig 3. The TM Model by the 69 represents 7,8-dihydropteroate, and mass input is modeled as a linear conversion into DHF 1 only by 70 dihydrofolate synthase (DFHS). Once DHF 1 is produced, it is converted into THF 1 via DHFR. TM inhibits all 71 DHFR activity. THF 1 is converted into THF 2 and then to THF 3 by FPGS, which also works on all THF n 72 derivatives (except 5MTHF n ), indicated by thin solid lines. Only FPGS carries out interconversions between 73 glutamation states. All FPGS activities have independent parameter sets. DHF n inhibits FPGS activity. TS 74 converts 510MTHF n to DHF n . SHMT converts THF n to 510MTHF n , and MTHFR converts 510mTHF n to 75 5MTHF n . MS does not convert monoglutamates of 5MTHF n to THF n , but its arrow is shown as other 76 enzymes for simplicity. DHF n is converted into pAB n and Pte n , which act as sinks for the system. 77 Experimental concentration data exists for all metabolites shown in the figure. Pte n inhibits TS and MS, 78 THF n inhibits SHMT, and 510MTHF n inhibits MTHFR. These inhibitions however are not as strong as that of 79 TM on DHFR. Formyl THF n derivatives were not included due to a lack of experimental data. 
223
The discrete simulation of THF n and its derivatives allows for accurate modeling of THF n 224 interconversions to and from its derivative forms. These interconversions feature inhibitory 225 interactions within the network such as Pte n inhibition of TS. In addition, the inhibition of FPGS 226 by DHF n can be included, affecting FPGS' activity on THF n and all its derivatives in varying degrees 227 (Fig 2) . Table 1 . The overall SSE is driven mainly by inaccuracy in 5mTHF 3 .
246
THF n follows the progression seen in the TM Model, and DHF n drops in concentration in 247 the Rewired Model instead of increasing as it does in the TM Model, which is potentially 248 problematic, since DHF n is a primary driver of the effect of TM. However, our objective is to find 249 an alternative and get a disruption in glutamation mix of folates that disrupt cellular metabolism.
250 Our goal is not simply to replicate the domino effect of TM, which causes a spike in DHF n and 251 then inhibits FPGS. 510mTHF n and 5mTHF n generally (with exception of 5mTHF 3 ) follow the same 252 time course progression in the Rewired Model as in the TM Model, which is encouraging. THF n 253 and its derivatives are more critical to cell functionality due to their connection to the rest of 254 cellular metabolism [8, 9] . The drop in DHF n introduces an interesting feature of the Rewired 255 Model.
256
Despite a poor match to experimental data and the TM Model with respect to DHF n , this 257 proposed set of drug targets may replicate the clinical effect of TM and Sulfamethoxazole.
258 Paradoxically, the drop in DHF n replicates the task of the drug Sulfamethoxazole, which is used 259 clinically with TM (the target of this drug target search effort). Sulfamethoxazole targets the 260 enzyme DHFS, which synthesizes DHF 1 and therefore inputs mass into the folate network.
261 Sulfamethoxazole and TM clinically work together to fully shut down flux into and within the 262 folate network [10, 16, 20] . The proposed inhibitors in the Rewired Model also appear to 263 severely lower the amount of cellular DHF n , which is achieved clinically by Sulfamethoxazole. This 264 means that the proposed set of inhibitors would be effective against some bacterial strains that 265 show resistance to TM and Sulfamethoxazole simultaneously. This is an unexpected but welcome
